Pharma company investors call for clinical trials transparency
23 July 2015
We’re delighted to announce that investors representing more than €3.5 trillion in assets are supporting the AllTrials campaign.
The group of 85 pension funds and asset managers are asking pharmaceutical companies to set out their plans to get clinical trials, past, present and future, registered and results reported.
Síle Lane, Director of Campaigns, Sense About Science, co-founder of the AllTrials campaign said: “For those who thought they could ignore AllTrials, those who thought they could ignore public calls for transparency, and those who thought no one was checking their compliance with the rules, here’s a clear message from investors: Wake up.”
BNP Paribas Investment Partners worked with AllTrials to bring together the group which includes RobecoSAM, Aviva Investors, Boston Commons Asset Management, 65 UK local authority pension funds and the investment arm of the Wellcome Trust. AllTrials and BNP Paribas Investment Partners ran workshops with investors to develop the steps they are calling on companies to take. Read those steps here.
Helena Viñes Fiestas, Head of Sustainability Research, BNP Paribas Investment Partners: “Alongside doctors and their patients, investors also risk being misled, given that an average of around 30% of pharmaceutical company valuations directly relates to the results of Phase III clinical trials. With company valuations and expected revenue streams a key component of the stock selection process, it is essential that companies publish complete and accurate information on trial results so that investment decisions can be fully informed.”
Source: Sense About Science